These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28748457)

  • 1. Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.
    Barrow PC; Schmitt G
    Methods Mol Biol; 2017; 1641():25-67. PubMed ID: 28748457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of juvenile toxicity.
    Barrow PC; Barbellion S; Stadler J
    Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Points to Consider in Designing and Conducting Juvenile Toxicology Studies.
    Kim NN; Parker RM; Weinbauer GF; Remick AK; Steinbach T
    Int J Toxicol; 2017; 36(4):325-339. PubMed ID: 28466670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of juvenile animal studies: a Japanese industry perspective.
    Shimomura K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):266-8. PubMed ID: 21594974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label.
    Baldrick P
    Ther Innov Regul Sci; 2018 Sep; 52(5):641-648. PubMed ID: 29714556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling.
    Tassinari MS; Benson K; Elayan I; Espandiari P; Davis-Bruno K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):261-5. PubMed ID: 21594977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of juvenile animal testing for small and large molecules.
    Baldrick P
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):125-35. PubMed ID: 23896345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile toxicity: are we asking the right questions?
    Downes N
    Toxicol Pathol; 2012 Jul; 40(5):830-7. PubMed ID: 22407308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical support of pediatric drug development in a global context: an industry perspective.
    Cappon GD
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):269-72. PubMed ID: 21594976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile animal testing in drug development--is it useful?
    Baldrick P
    Regul Toxicol Pharmacol; 2010; 57(2-3):291-9. PubMed ID: 20350578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative juvenile safety testing of new therapeutic candidates: relevance of laboratory animal data to children.
    Anderson T; Khan NK; Tassinari MS; Hurtt ME
    J Toxicol Sci; 2009; 34 Suppl 2():SP209-15. PubMed ID: 19571471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of juvenile animal studies.
    Leconte I; Bailey G; Davis-Bruno K; Hew KW; Kim J; Silva Lima B; Liminga U; Moffit J; De Schaepdrijver L; Schmitt G; Tassinari M; Thompson K; Hurtt M
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):292-303. PubMed ID: 22623020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.